Get started
Author

Pantelis Rousakis

Observed names: P. Rousakis, P. Roussakis, Pantelis Roussakis, Rousakis, Pantelis, Ρουσάκης, Παντελής
ORCID: 0000-0003-3853-4043
Observed ORCID: 0000-0003-3853-4043
OpenAlex ID: A5023354368
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion
2021 · Vassilis L. Tzounakas, Alkmini T. Anastasiadi, et al. · Haematologica · 43
PDF
Next generation flow cytometry for MRD detection in patients with AL amyloidosis
2020 · Esftathios Kastritis, Ioannis V. Kostopoulos, et al. · Amyloid · 35
Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming
2023 · Ioannis S. Pateras, Chloe Williams, et al. · Journal of Translational Medicine · 32
PDF
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
2020 · Nikolaos Orologas-Stavrou, Marianna Politou, et al. · Viruses · 32
PDF
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report
2020 · Ourania E. Tsitsilonis, Dimitrios Paraskevis, et al. · Life · 32
PDF
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
2019 · Evangelos Terpos, Ioannis V. Kostopoulos, et al. · HemaSphere · 31
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
2020 · Tina Bagratuni, Dimitrios Patseas, et al. · Cancers · 30
PDF
Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More
2022 · Ioannis V. Kostopoulos, Ioannis Ntanasis-Stathopoulos, et al. · Journal of Clinical Oncology · 22
PDF
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease
2021 · Efstathios Kastritis, Pantelis Rousakis, et al. · Amyloid · 22
PDF
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
2021 · Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, et al. · Cancers · 21
PDF
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
2021 · Ioannis V. Kostopoulos, Nikolaos Orologas-Stavrou, et al. · Microorganisms · 19
PDF
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
2021 · Ourania E. Tsitsilonis, Dimitrios Paraskevis, et al. · Vaccines · 14
PDF
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
2024 · Ioannis V. Kostopoulos, Ioannis Ntanasis‐Stathopoulos, et al. · American Journal of Hematology · 12
PDF
Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients
2022 · Ioannis V. Kostopoulos, Antonis Kakalis, et al. · American Journal of Hematology · 11
PDF
Prognostic Significance of Endocrine-Related Adverse Events in Patients with Melanoma, Non-Small Cell Lung Cancer and Urothelial Cancer After Treatment with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2025 · Stylianos Kopanos, Charalampos Filippatos, et al. · Cancers · 5
PDF
Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line Treatment
2025 · Polyxeni Spiliopoulou, Pantelis Rousakis, et al. · Scandinavian Journal of Medicine and Science in Sports · 4
PDF
The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous Transplantation
2025 · Polyxeni Spiliopoulou, Pantelis Rousakis, et al. · Onco · 3
PDF
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
2024 · Ioannis V. Kostopoulos, Despina Fotiou, et al. · Blood Cancer Journal · 3
PDF
Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients
2023 · Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, et al. · Blood · 3
Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes
2021 · Despina Fotiou, Ioannis V Kostopoulos, et al. · Blood · 3
Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment
2020 · Efstathios Kastritis, Pantelis Roussakis, et al. · Blood · 2
Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus
2026 · Polyxeni Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, et al. · Sports · 1
PDF
Detection and Characterization of Senescent Cells with Flow Cytometry
2025 · Panagiotis Bakouros, Ariadni Archavli, et al. · Methods in molecular biology · 1
A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
2024 · Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, et al. · Blood · 1
Pb2124: Efficacy and Immune Modulation of Daratumumab Plus Imid Combination in Patients Refractory to Both Agents“
2023 · Ioannis Kostopoulos, Despoina Fotiou, et al. · HemaSphere · 1
Works count: 53
Citation count: 384
H-index: 12
I10-index: 14
Year
Topic
Type